14
views
0
recommends
+1 Recommend
2 collections
    0
    shares

      Call for Papers: Digital Diagnostic Techniques

      Submit here before November 30, 2024

      About Pathobiology: 3.5 Impact Factor I 8.5 CiteScore I 1.088 Scimago Journal & Country Rank (SJR)

      Call for Papers: Supportive Care - Essential for Modern Oncology

      Submit here before December 31, 2024

      About Oncology Research and Treatment: 2.0 Impact Factor I 3.2 CiteScore I 0.521 Scimago Journal & Country Rank (SJR)

      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Synchronous Primary Lung Cancers Containing Discrete Driver Mutations in a Never-Smoker: Case Report

      case-report

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Although most lung cancer patients present with one primary cancer, some present with multiple lung cancers of different clonal origin. Timely recognition of synchronous multifocal primary lung cancer (MPLC) enables distinct treatment regimens that reflect the unique genotypic makeup and location of each cancer. However, recognition of synchronous MPLCs is challenging given the prevalence of multifocal disease. Here, we report a case of a patient diagnosed with anaplastic lymphoma kinase, termed ALK, positive metastatic lung adenocarcinoma whose follow-up computerized tomography (CT) imaging identified one lesion, present since the patient’s initial presentation, with a distinctly different response to treatment than other lesions. Biopsy results showed a distinct MPLC, an epidermal growth factor receptor ( EGFR)-positive adenocarcinoma with no evidence of an ALK mutation. The EGFR lesion was treated with curative intent via surgical resection while the ALK disease was managed with palliative intent via targeted therapy. To our knowledge, there have been no other reports of two synchronous MPLCs of an adenocarcinoma subtype with completely distinct EGFR and ALK driver mutations. This case highlights the importance of serial follow-up imaging, combined with biopsy of lesions with atypical treatment responses, as a method for identifying synchronous MPLCs and adjusting treatment to optimize patient outcomes.

          Related collections

          Most cited references17

          • Record: found
          • Abstract: found
          • Article: not found

          Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

          This article provides an update on the global cancer burden using the GLOBOCAN 2020 estimates of cancer incidence and mortality produced by the International Agency for Research on Cancer. Worldwide, an estimated 19.3 million new cancer cases (18.1 million excluding nonmelanoma skin cancer) and almost 10.0 million cancer deaths (9.9 million excluding nonmelanoma skin cancer) occurred in 2020. Female breast cancer has surpassed lung cancer as the most commonly diagnosed cancer, with an estimated 2.3 million new cases (11.7%), followed by lung (11.4%), colorectal (10.0 %), prostate (7.3%), and stomach (5.6%) cancers. Lung cancer remained the leading cause of cancer death, with an estimated 1.8 million deaths (18%), followed by colorectal (9.4%), liver (8.3%), stomach (7.7%), and female breast (6.9%) cancers. Overall incidence was from 2-fold to 3-fold higher in transitioned versus transitioning countries for both sexes, whereas mortality varied <2-fold for men and little for women. Death rates for female breast and cervical cancers, however, were considerably higher in transitioning versus transitioned countries (15.0 vs 12.8 per 100,000 and 12.4 vs 5.2 per 100,000, respectively). The global cancer burden is expected to be 28.4 million cases in 2040, a 47% rise from 2020, with a larger increase in transitioning (64% to 95%) versus transitioned (32% to 56%) countries due to demographic changes, although this may be further exacerbated by increasing risk factors associated with globalization and a growing economy. Efforts to build a sustainable infrastructure for the dissemination of cancer prevention measures and provision of cancer care in transitioning countries is critical for global cancer control.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Osimertinib in Untreated EGFR-Mutated Advanced Non–Small-Cell Lung Cancer

            Osimertinib is an oral, third-generation, irreversible epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that selectively inhibits both EGFR-TKI-sensitizing and EGFR T790M resistance mutations. We compared osimertinib with standard EGFR-TKIs in patients with previously untreated, EGFR mutation-positive advanced non-small-cell lung cancer (NSCLC).
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer

              Standard first-line therapy for metastatic, squamous non-small-cell lung cancer (NSCLC) is platinum-based chemotherapy or pembrolizumab (for patients with programmed death ligand 1 [PD-L1] expression on ≥50% of tumor cells). More recently, pembrolizumab plus chemotherapy was shown to significantly prolong overall survival among patients with nonsquamous NSCLC.
                Bookmark

                Author and article information

                Journal
                Case Rep Oncol
                Case Rep Oncol
                CRO
                CRO
                Case Reports in Oncology
                S. Karger AG (Basel, Switzerland )
                1662-6575
                14 November 2023
                Jan-Dec 2023
                14 November 2023
                : 16
                : 1
                : 1384-1389
                Affiliations
                [a ]Drexel University College of Medicine, Philadelphia, PA, USA
                [b ]University of Pennsylvania, Philadelphia, PA, USA
                [c ]Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA
                Author notes
                Correspondence to: Andrew Davis, ajd426@ 123456drexel.edu
                Article
                533892
                10.1159/000533892
                10645435
                e8bc3975-22fc-4269-9ae4-3a9ae490bce7
                © 2023 The Author(s). Published by S. Karger AG, Basel

                This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) ( http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.

                History
                : 30 May 2023
                : 28 August 2023
                : 2023
                Page count
                Figures: 2, References: 17, Pages: 6
                Funding
                This research did not receive any specific Grant from funding agencies in the public, commercial, or not-for-profit sectors.
                Categories
                Case Report

                Oncology & Radiotherapy
                synchronous multifocal primary lung cancer,synchronous non-small cell lung cancer,case report,anaplastic lymphoma kinase,epidermal growth factor receptor

                Comments

                Comment on this article